Acta Diabetologica

, Volume 51, Issue 3, pp 447–453 | Cite as

Different prevalence of metabolic control and chronic complication rate according to the time of referral to a diabetes care unit in the elderly

  • Felice Strollo
  • Giuseppina Guarino
  • Giampiero Marino
  • Giuseppe Paolisso
  • Sandro Gentile
Original Article

Abstract

The time of diagnosis is crucial for type 2 diabetes mellitus (T2DM) in terms of disease severity and chronic complications, as initial glycated haemoglobin (HbA1c) predicts 5-year cardiovascular mortality. The Italian health-care system relies on about 650 diabetes care units (DCU) interfacing with a large number of general practitioners (GPs). It may thus reach the goal of preventing complications easier than others by adopting a more comprehensive multifactorial approach. To assess whether the interval between diagnosis and referral to the DCU might influence the course of the disease in terms of HbA1c, associated cardiovascular risk factors, drug utilisation, and chronic complications in the elderly, the electronic records of 313 elderly T2DM patients (74.6 ± 4.9 years) followed by their GPs until referral to our DCU were retrospectively analysed for the above-mentioned parameters and divided into an early referral (ER) group (diagnosed within 12 months, n = 111) and a late referral (LR) group (diagnosed >12 months before, n = 202). A further set of 200 patients routinely taken care by our DCU, matched with the LR group for age, gender, and disease duration, was classified as “long-standing follow-up” (LSF) and compared to the others to rule out any confounding effects of long-standing disease per se on the clinical outcomes investigated in our study. About 35 % of T2DM patients referred to our DCU within 12 months of diagnosis; the rest did so some 5 years after diagnosis. LR patients displayed worse HbA1c levels (10.8 vs. 7.7 %, p < 0.01), used more drugs, and had more than twice as high complication rates as their ER counterparts. Almost all risk factors and complications were lower in the LSF (0.001 < p < 0.05) and ER groups than in the LR group. In both the ER and the LSF groups, we observed a lower burden of diabetes than in the LR group. This rules out the possibility that disease duration might play a major role per se in the burden of the disease in the elderly as opposed to the thoughtful patient care attitude exhibited by the DCU. A better and more efficient organisation has to be developed, including a strong interaction among GPs, diabetes specialists, and elderly people with T2DM allowing the latter to take charge of their own disease management through a sustained empowerment policy.

Keywords

Type 2 diabetes mellitus Elderly Costs Diabetes care unit Disease management 

References

  1. 1.
    Kerr D, Partridge H, Knott J, Thomas PW (2011) HbA1c 3 months after diagnosis predicts premature mortality in patients with new onset type 2 diabetes. Diabet Med 28:1520–1524PubMedCrossRefGoogle Scholar
  2. 2.
    Ceriello A, Ihnat MA, Thorpe JE (2009) Clinical review 2: the “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 94:410–415PubMedCrossRefGoogle Scholar
  3. 3.
    Ceriello A (2012) The emerging challenge in diabetes: the “metabolic memory”. Vascul Pharmacol 57:133–138PubMedCrossRefGoogle Scholar
  4. 4.
    Monnier L, Colette C, Owens D (2012) The glycemic triumvirate and diabetic complications: is the whole greater than the sum of its component parts? Diabetes Res Clin Pract 95:303–311PubMedCrossRefGoogle Scholar
  5. 5.
    Nalysnyk L, Hernandez-Medina M, Krishnarajah G (2010) Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 12:288–298PubMedCrossRefGoogle Scholar
  6. 6.
    Kilpatrick ES, Rigby AS, Atkin SL (2010) For debate. Glucose variability and diabetes complication risk: we need to know the answer. Diabet Med 27:868–871PubMedCrossRefGoogle Scholar
  7. 7.
    Turner RC, Holman RR, Cull CA et al (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRefGoogle Scholar
  8. 8.
    Pedersen O, Gaede P (2003) Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study. Metabolism 52:19–23PubMedCrossRefGoogle Scholar
  9. 9.
    Appropriatezza clinica, strutturale, tecnologica e operative per la prevenzione, diagnosi e terapia dell’obesità e del diabete mellito. Quaderni del Ministero della salute n.10. Poligrafico dello Stato, Roma 2011. Last access on 4 Oct 2013: http://www.quadernidellasalute.it/archivio-quaderni/10-luglio-agosto-2011.php
  10. 10.
    Giorda C, Petrelli A, Gnavi R et al (2006) impact of second-level specialized care on hospitalization in persons with diabetes: a multilevel population-based study. Diabet Med 23:377–383PubMedCrossRefGoogle Scholar
  11. 11.
    Watanabe RM (2011) Drugs, diabetes and pharmacogenomics: the road to personalized therapy. Pharmacogenomics 12:699–701PubMedCrossRefGoogle Scholar
  12. 12.
    Giorda C, Picariello R, Nada E et al (2012) The impact of adherence to screening guidelines and of diabetes clinics referral on morbidity and mortality in diabetes. PLoS One 7:e33839. doi:10.1371/journal.pone.0033839 PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Tur J, Alòs M, Iglesias L et al (2011) TRAMOMTANA (Multidisciplinary treatment of morbid obesity: medication, behavioral therapy, nutritional support, and physical activity). From question to reality in an investigator-initiated clinical trial (II). Endocrinol Nutr 58:299–307PubMedCrossRefGoogle Scholar
  14. 14.
    Aggarwal C, Langer CJ (2012) Older age, poor performance status and major comorbidities: how to treat high-risk patients with advanced nonsmall cell lung cancer. Curr Opin Oncol 24:130–136PubMedCrossRefGoogle Scholar
  15. 15.
    Bauman AE, Reis RS, Sallis JF et al (2012) Correlates of physical activity: why are some people physically active and others not? Lancet 380:258–271PubMedCrossRefGoogle Scholar
  16. 16.
    Mathus-Vliegen EM (2012) Obesity management task force of the European association for the study of obesity. Prevalence, pathophysiology, health consequences and treatment options of obesity in the elderly: a guideline. Obes Facts 5:460–483PubMedCrossRefGoogle Scholar
  17. 17.
    Nouwens E, van Lieshout J, Wensing M (2012) Comorbidity complicates cardiovascular treatment: is diabetes the exception? Neth J Med 70:298–305PubMedGoogle Scholar
  18. 18.
    Bruno G, De Micheli A, Frontoni S et al (2011) Highlights from “Italian Standards of Care for Diabetes Mellitus 2009–2010”. Nutr Metab Cardiovasc Dis 21:302–314PubMedGoogle Scholar
  19. 19.
    Schernthaner G (2010) Diabetes and cardiovascular disease: is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wien Med Wochenschr 160:8–19PubMedCrossRefGoogle Scholar
  20. 20.
    Terry T, Raravikar K, Chokrungvaranon K, Reaven PD (2012) Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes?: insights from ACCORD, ADVANCE, and VADT. Curr Cardiol Rep 14:79–88PubMedCrossRefGoogle Scholar
  21. 21.
    Rana OA, Byrne CD, Greaves K. (2013) Intensive glucose control and hypoglycaemia: a new cardiovascular risk factor? Heart. doi: 10.1136/heartjnl-2013-303871
  22. 22.
    Hemmingsen B, Lund SS, Gluud C et al (2011) Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 343:d6898. doi:10.1136/bmj.d6898 PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Arcangeli A, Cimino A, Di Bartolo P et al. (2012) Gruppo Annali AMD. Analisi prospettica degli indicatori di qualità dell’assistenza del diabete in Italia (2004–2011). http://www.infodiabetes.it/files/ANNALI-AMD/2012/Annali2012.pdf
  24. 24.
    Rossi MC, Lucisano G, Comaschi M et al (2011) AMD-QUASAR Study Group. Quality of diabetes care predicts the development of cardiovascular events: results of the AMD-QUASAR Study. Diabetes Care 34:347–352PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Gruppo di studio ANNALI AMD (2011) AMD Annals: a model of continuous monitoring and improvement of the quality of diabetes care. Epidemiol Prev 35:18–26Google Scholar
  26. 26.
    Motta AJ, Koska J, Reaven P, Migrino RQ (2012) Vascular protective effects of diabetes medications that mimic or increase glucagon-like peptide-1 activity. Recent Pat Cardiovasc Drug Discov. 7:2–9PubMedCrossRefGoogle Scholar
  27. 27.
    Vilsbøll T, Garber AJ (2012) Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. Diabetes Obes Metab 14(Suppl 2):41–49PubMedCrossRefGoogle Scholar
  28. 28.
    Fonseca VA (2011) Incretin-based therapies in complex patients: practical implications and opportunities for maximizing clinical outcomes: a discussion with Dr. Vivian A. Fonseca. Am J Med. 124(1 Suppl):S54–S61PubMedCrossRefGoogle Scholar
  29. 29.
    Kruger DF, Boucher JL, Banerji MA (2011) Utilizing current diagnostic criteria and treatment algorithms for managing type 2 diabetes mellitus. Postgrad Med 123:54–62PubMedCrossRefGoogle Scholar
  30. 30.
    Gnavi R, Picariello R, la Karaghiosoff L et al (2009) Determinants of quality in diabetes care process: the population-based Torino study. Diabetes Care 32:1986–1992PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Ziemer DC, Doyle JP, Barnes CS, Branch CT Jr, Cook CB, El-Kebbi IM, Gallina DL, Kolm P, Rhee MK, Phillips LS (2006) An intervention to overcome clinical inertia and improve diabetes mellitus control in a primary care setting. Improving primary care of African Americans with diabetes (IPCAAD) 8. Arch Intern Med 166:507–513PubMedCrossRefGoogle Scholar
  32. 32.
    Shah BR, Hux JE, Laupacis A, Zinman B, Van Walraven C (2005) Clinical inertia in response to inadequate glycemic control. Do specialists differ from primary care physicians? Diabetes Care 28:600–606PubMedCrossRefGoogle Scholar
  33. 33.
    van Bruggen R, Gorter K, Stolk R, Klungel O, Rutten G (2009) Clinical inertia in general practice: widespread and related to the outcome of diabetes care. Fam Pract 26:428–436PubMedCrossRefGoogle Scholar
  34. 34.
    Bruno G, Picariello R, Petrelli A et al (2012) Direct costs in diabetic and non diabetic people: the population-based Turin study, Italy. Nutr Metab Cardiovasc Dis 22:684–690PubMedCrossRefGoogle Scholar
  35. 35.
    Ceriello A, Candido R, De Micheli A, Esposito K, Gallo M, Gentile S, Medea G (for the SIMG). Personalisation of therapy in type 2 diabetes. Last access, 26 May 2013 http://www.aemmedi.it/algoritmi_en_2013/intro-english.html

Copyright information

© Springer-Verlag Italia 2013

Authors and Affiliations

  • Felice Strollo
    • 1
  • Giuseppina Guarino
    • 2
  • Giampiero Marino
    • 2
  • Giuseppe Paolisso
    • 3
  • Sandro Gentile
    • 2
  1. 1.Endocrine-Metabolic UnitINRCARomeItaly
  2. 2.Department of Clinical and Experimental Medicine2nd University of NaplesNaplesItaly
  3. 3.Department of Geriatrics and Metabolic Diseases2nd University of NaplesNaplesItaly

Personalised recommendations